Providence St. Joseph Health appointed Venkat Bhamidipati as executive vice president and chief financial officer, effective July 31.
Aliso Viejo-based Inceptus Medical LLC said it helped Okami Medical Inc. raise a $4.5 million series B financing from U.S. Venture Partners in Menlo Park and other individual investors.
Irvine-based medical device company Rebound Therapeutics Corp. raised $16.5 million in Series B financing.
Allegro Ophthalmics LLC in San Juan Capistrano raised $10.7 million in equity financing. Terms were not disclosed.
HEALTHCARE: CEO says there are a number of applications
Cianna Medical Inc., a medical device company in Aliso Viejo that focuses on developing devices used in breast cancer treatment, plans to aggressively grow the company with its latest Scout radar localization technology, which received Food and Drug Administration approval late last year.
HEALTHCARE: Unlike prior deal, not looking to exit via sale
When Sarepta Therapeutics Inc. announced Douglas Ingram as president and chief executive officer, the general consensus was that the Cambridge, Mass.-based biotech company tapped the former Allergan president to execute a buyout, given Ingram’s past experiences at Allergan PLC and Chase Pharmaceuticals Corp.
HEALTHCARE: Develops more resilient tissue, ‘first-of-its-kind’
Edwards Lifesciences Corp. received Food and Drug Administration approval for a new aortic heart valve, Inspiris Resilia.
Workplace Design Enables Safety, Healing, Teamwork
People interact with buildings on a daily basis—in workplaces, neighborhoods and the places of business we frequent. In fact, we spend quite a lot of time inside them, and our behaviors are influenced by our surroundings.
Urine-Based Test Aims to Cut Invasive Procedures
MDxHealth SA in Irvine has rolled out its third test, AssureMDx. The noninvasive urine-based test assesses the risk of bladder cancer in patients diagnosed with hematuria—blood in the urine.
Company Now in OC, Targets U.S., China Growth
Dendreon Pharmaceuticals LLC received the Food and Drug Administration’s thumbs-up for its prostate-cancer therapy Provenge in 2010, and analysts projected $4.3 billion in annual sales by 2020, yet it was a blockbuster that failed to premiere.